Is Zosano Pharma Corp (ZSAN) Stock Near the Top of the Biotechnology Industry?

Wednesday, August 12, 2020 11:47 AM | InvestorsObserver Analysts

Zosano Pharma Corp (ZSAN) is near the top in its industry group according to InvestorsObserver. ZSAN gets an overall rating of 76. That means it scores higher than 76 percent of stocks. Zosano Pharma Corp gets a 88 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Overall Score - 76
ZSAN has an Overall Score of 76. Find out what this means to you and get the rest of the rankings on ZSAN!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 76 means the stock is more attractive than 76 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Zosano Pharma Corp Stock Today?

Zosano Pharma Corp (ZSAN) stock has fallen -12.66% while the S&P 500 has risen 1.27% as of 11:44 AM on Wednesday, Aug 12. ZSAN is lower by -$0.19 from the previous closing price of $1.54 on volume of 7,226,662 shares. Over the past year the S&P 500 is up 15.37% while ZSAN is lower by -55.30%. ZSAN lost -$1.82 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Close Update: Stocks Rally Friday Led by Technology to End Week Mixed

Wild Week Ends Up K Shaped

Sector Update: Biotech Stocks Lifting Health Care Sector to Big Advance

Stocks Shrug Off Early Weakness, Poised to Close Sharply Higher

Sector Update: Health Care

Is it Time to Dump Columbia Care Inc (CCHWF) Stock After it Is Down 4.62% in a Week?

Related Companies